KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer

Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.